Pelviperitonitis gonocócica. A propósito de un caso / Gonococcal pelviperitonitis. A case report

Neisseria gonorrhoeae se considera uno de los agentes causales más importantes de la enfermedad pélvica inflamatoria (EPI) produciendo síntomas leves e inespecíficos, lo cual la convierte en un desafío diagnóstico. Se presenta un caso de una pelviperitonitis gonocócica aguda con dolor difuso, distensión abdominal, fiebre. El único hallazgo destacable fue un líquido peritoneal y endocervical purulento con reactantes de fase aguda elevados. El cultivo del líquido endocervical y peritoneal fue positivo para N. gonorrhoeae. En mujeres sexualmente activas y con sospecha de EPI es importante descartar enfermedades de transmisión sexual.

Neisseria gonorrhoeae is considered one of the most important causal agents of pelvic inflammatory disease, producing mild and nonspecific symptoms, which makes it a diagnostic challenge. A case of acute gonococcal pelviperitonitis with abdominal distension, fever and diffuse pain is presented. The only noteworthy finding was purulent peritoneal and endocervical fluid with elevated acute-phase reactants. Endocervical and peritoneal fluid culture showed infection with N. gonorrhoeae. Therefore, in sexually active women with suspected PID, it is important to rule out sexually transmitted diseases.

Antibiotic therapy for pelvic inflammatory disease.

BACKGROUND: Pelvic inflammatory disease (PID) affects 4% to 12% of women of reproductive age. The main intervention for acute PID is broad-spectrum antibiotics administered intravenously, intramuscularly or orally. We assessed the optimal treatment regimen for PID.  OBJECTIVES: To assess the effectiveness and safety of antibiotic regimens to treat PID. SEARCH METHODS: In January 2020, we searched the Cochrane Sexually Transmitted Infections Review Group's Specialized Register, which included randomized controlled trials (RCTs) from 1944 to 2020, located through hand and electronic searching; CENTRAL; MEDLINE; Embase; four other databases; and abstracts in selected publications. SELECTION CRITERIA: We included RCTs comparing antibiotics with placebo or other antibiotics for the treatment of PID in women of reproductive age, either as inpatient or outpatient treatment. We limited our review to a comparison of drugs in current use that are recommended by the 2015 US Centers for Disease Control and Prevention guidelines for treatment of PID. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. Two authors independently extracted data, assessed risk of bias and conducted GRADE assessments of the quality of evidence. MAIN RESULTS: We included 39 RCTs (6894 women) in this review, adding two new RCTs at this update. The quality of the evidence ranged from very low to high, the main limitations being serious risk of bias (due to poor reporting of study methods and lack of blinding), serious inconsistency, and serious imprecision. None of the studies reported quinolones and cephalosporins, or the outcomes laparoscopic evidence of resolution of PID based on physician opinion or fertility outcomes. Length of stay results were insufficiently reported for analysis. Regimens containing azithromycin versus regimens containing doxycycline We are uncertain whether there was a clinically relevant difference between azithromycin and doxycycline in rates of cure for mild-moderate PID (RR 1.18, 95% CI 0.89 to 1.55; 2 RCTs, 243 women; I2 = 72%; very low-quality evidence). The analyses may result in little or no difference between azithromycin and doxycycline in rates of severe PID (RR 1.00, 95% CI 0.96 to 1.05; 1 RCT, 309 women; low-quality evidence), or adverse effects leading to discontinuation of treatment (RR 0.71, 95% CI 0.38 to 1.34; 3 RCTs, 552 women; I2 = 0%; low-quality evidence). In a sensitivity analysis limited to a single study at low risk of bias, azithromycin probably improves the rates of cure in mild-moderate PID (RR 1.35, 95% CI 1.10 to 1.67; 133 women; moderate-quality evidence), compared to doxycycline.  Regimens containing quinolone versus regimens containing cephalosporin The analysis shows there may be little or no clinically relevant difference between quinolones and cephalosporins in rates of cure for mild-moderate PID (RR 1.05, 95% CI 0.98 to 1.14; 4 RCTs, 772 women; I2 = 15%; low-quality evidence), or severe PID (RR 1.06, 95% CI 0.91 to 1.23; 2 RCTs, 313 women; I2 = 7%; low-quality evidence). We are uncertain whether there was a difference between quinolones and cephalosporins in adverse effects leading to discontinuation of treatment (RR 2.24, 95% CI 0.52 to 9.72; 6 RCTs, 1085 women; I2 =  0%; very low-quality evidence). Regimens with nitroimidazole versus regimens without nitroimidazole There was probably little or no difference between regimens with or without nitroimidazoles (metronidazole) in rates of cure for mild-moderate PID (RR 1.02, 95% CI 0.95 to 1.09; 6 RCTs, 2660 women; I2 = 50%; moderate-quality evidence), or severe PID (RR 0.96, 95% CI 0.92 to 1.01; 11 RCTs, 1383 women; I2 = 0%; moderate-quality evidence). The evidence suggests that there was little to no difference in in adverse effects leading to discontinuation of treatment (RR 1.05, 95% CI 0.69 to 1.61; 17 studies, 4021 women; I2 = 0%; low-quality evidence). . In a sensitivity analysis limited to studies at low risk of bias, there was little or no difference for rates of cure in mild-moderate PID (RR 1.05, 95% CI 1.00 to 1.12; 3 RCTs, 1434 women; I2 = 0%; high-quality evidence). Regimens containing clindamycin plus aminoglycoside versus quinolone We are uncertain whether quinolone have little to no effect in  rates of cure for mild-moderate PID compared to clindamycin plus aminoglycoside (RR 0.88, 95% CI 0.69 to 1.13; 1 RCT, 25 women; very low-quality evidence). The analysis may result in little or no difference between quinolone vs. clindamycin plus aminoglycoside in severe PID (RR 1.02, 95% CI 0.87 to 1.19; 2 studies, 151 women; I2 =  0%; low-quality evidence). We are uncertain whether quinolone reduces adverse effects leading to discontinuation of treatment (RR 0.21, 95% CI 0.02 to 1.72; 3 RCTs, 163 women; I2 =  0%; very low-quality evidence). Regimens containing clindamycin plus aminoglycoside versus regimens containing cephalosporin We are uncertain whether clindamycin plus aminoglycoside improves the rates of cure for mild-moderate PID compared to cephalosporin (RR 1.02, 95% CI 0.95 to 1.09; 2 RCTs, 150 women; I2 =  0%; low-quality evidence). There was probably little or no difference in rates of cure in severe PID with clindamycin plus aminoglycoside compared to cephalosporin (RR 1.00, 95% CI 0.95 to 1.06; 10 RCTs, 959 women; I2= 21%; moderate-quality evidence). We are uncertain whether clindamycin plus aminoglycoside reduces adverse effects leading to discontinuation of treatment compared to cephalosporin (RR 0.78, 95% CI 0.18 to 3.42; 10 RCTs, 1172 women; I2 =  0%; very low-quality evidence). AUTHORS' CONCLUSIONS: We are uncertain whether one treatment was safer or more effective than any other for the cure of mild-moderate or severe PID Based on a single study at a low risk of bias, a macrolide (azithromycin) probably improves the rates of cure of mild-moderate PID, compared to tetracycline (doxycycline).

A Need for Standardization of the Diagnosis and Treatment of Pelvic Inflammatory Disease: Pilot Study in an Outpatient Clinic in Quito, Ecuador.

Background: Pelvic inflammatory disease (PID) diagnosis is often challenging as well as its treatment. This study sought to characterize the diagnostic and therapeutic trend among physicians at the outpatient level, in Quito, Ecuador, where currently no nationwide screening or specific clinical guideline has been implemented on PID or its main microbiological agents. Methods: A retrospective analysis of medical records with pelvic inflammatory disease diagnosis in an outpatient clinic was performed. Electronic medical records from 2013 to 2018 with any pelvic inflammatory disease-related diagnoses were retrieved. Information with regard to age, sexually related risk factors, symptoms and physical exam findings, ancillary tests, method of diagnosis, and antibiotic regimens was extracted. Results: A total of 186 records were included. The most frequent clinical manifestations were vaginal discharge (47%) and pelvic pain (39%). In the physical examination, leucorrhea was the most frequent finding (47%), followed by lower abdominal tenderness (35%) and cervical motion tenderness in 51 patients (27%). A clinical diagnosis was established in 60% of patients, while 37% had a transvaginal sonography-guided diagnosis. Antibiotic treatment was prescribed with standard regimens in 3% of cases, while other regimens were used in 93% of patients. Additionally, an average of 1.9 drugs were prescribed per patient, with a range from 1 to 5, all in different combinations and dosages. Conclusions: No standardized methods of diagnosis or treatment were identifiable. These findings highlight the need for standardization of the diagnosis and treatment of PID attributed to chlamydial and gonococcal infections.

Ascitis secundaria a chlamydia trachomatis tras procedimiento de reproducción asistida / Ascites secondary to chlamydia trachomatis after assisted reproduction procedure

El desarrollo de ascitis moderada o severa es infrecuente tras una enfermedad inflamatoria pélvica por Chlamydia trachomatis, una de las principales causas de infección de transmisión sexual a nivel mundial. Caso clínico: Paciente de 29 años que tras aborto diferido (gestación tras inseminación artificial) que inicia a las seis semanas con cuadro de dolor abdominal inespecífico y ascitis de predominio linfocitario. El diagnostico se realizo mediante PCR (Werfen®) tanto el liquido ascítico como en exudado endocervical. La paciente recibió tratamiento antibiótico con doxiciclina. Conclusión: Las enfermedades de transmisión sexual deben ser consideradas cuando se realiza un diagnóstico diferencial de una mujer sexualmente activa con dolor abdominal y ascitis, instaurar tratamiento antibiótico y evitar pruebas e intervenciones quirúrgicas innecesarias.

The development of moderate or severe ascites is infrequent after a pelvic inflammatory disease from Chlamydia trachomatis, one of the main causes of sexually transmitted infection worldwide. Clinical case: A 29-year-old patient who, after a delayed abortion (gestation after artificial insemination), started at six weeks with symptoms of non-specific abdominal pain and predominantly lymphocytic ascites. The diagnosis is made by PCR (Werfen®) both the ascitic fluid and the endocervical exudate. The patient received antibiotic treatment with doxycycline. Conclusion: Sexually transmitted diseases should be considered when making a differential diagnosis of a sexually activated woman with abdominal pain and ascites. Establishing antibiotic treatment, and avoiding unnecessary tests and surgical treatments.

Antibiotic therapy for pelvic inflammatory disease: an abridged version of a Cochrane systematic review and meta-analysis of randomised controlled trials.

OBJECTIVE: To assess the effectiveness and safety of antibiotic regimens used to treat pelvic inflammatory disease (PID). DESIGN: This is a systematic review and meta-analysis of randomised controlled trials (RCTs). Risk of bias was assessed using the criteria outlined in the Cochrane guidelines. Quality of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation. DATA SOURCES: Eight electronic databases were searched from date of inception up to July 2016. Database searches were complemented by screening of reference lists of relevant studies, trial registers, conference proceeding abstracts and grey literature. ELIGIBILITY CRITERIA: RCTs comparing the use of antibiotics with placebo or other antibiotics for the treatment of PID in women of reproductive age, either as inpatient or outpatient treatment. RESULTS: We included 37 RCTs (6348 women). The quality of evidence ranged from very low to high, the main limitations being serious risk of bias (due to poor reporting of study methods and lack of blinding), serious inconsistency and serious imprecision. There was no clear evidence of a difference in the rates of cure for mild-moderate or for severe PID for the comparisons of azithromycin versus doxycycline, quinolone versus cephalosporin, nitroimidazole versus no use of nitroimidazole, clindamycin plus aminoglycoside versus quinolone, or clindamycin plus aminoglycoside versus cephalosporin. No clear evidence of a difference between regimens in antibiotic-related adverse events leading to discontinuation of therapy was observed. CONCLUSIONS: We found no conclusive evidence that one regimen of antibiotics was safer or more effective than any other for the treatment of PID, and there was no clear evidence for the use of nitroimidazoles (metronidazole) compared with the use of other drugs with activity against anaerobes. More evidence is needed to assess treatments for women with PID, particularly comparing regimens with or without the addition of nitroimidazoles and the efficacy of azithromycin compared with doxycycline.

Costo del tratamiento en trabajadoras con enfermedad inflamatoria pelviana / Cost of treatment in workers with pelvic inflammatory disease

Se realizó una intervención terapéutica en 39 trabajadoras con inflamación pelviana, diagnosticadas y tratadas desde hacía 5 meses, pertenecientes al área de salud "La Caoba" del municipio de San Luís, en Santiago de Cuba, de enero a mayo del 2012, con vistas a comparar el costo del tratamiento medicamentoso con el del acupuntural. En la serie se obtuvo que 51,3 % de las féminas con medicación mejorara en 2 semanas y 23,1 % requirió más de 28 días de tratamiento, mientras que 90,0 % de las que recibieron acupuntura se recuperaron en 3 semanas. Esta terapéutica alternativa constituyó un ahorro para las pacientes, al disminuir sus pérdidas económicas por gastos en medicamentos y por certificados médicos; además de reducir la estadía hospitalaria y su costo. Desde el punto de vista social se logró que las trabajadoras afectadas se incorporaran a sus quehaceres laborales y domésticos más tempranament.

A therapeutic intervention was carried out in 39 workers with pelvic inflammation, diagnosed and treated for 5 months, belonging to the health area from "La Caoba" of San Luís municipality, in Santiago de Cuba, from January to May, 2012, with the aim of comparing the cost of drug treatment with that of the acupunctural treatment. In the series it was obtained that 51.3% of the female with medication improved in 2 weeks and 23.1% required more than 28 days of treatment, while 90.0% of those who received acupuncture recovered in 3 weeks. This alternative therapy constituted a saving for the patients, as they decreased their economic losses due to expenses in medications and to medical certificates; besides reducing the hospital stay and its cost. From the social point of view it was achieved that the affected workers incorporate to their jobs and domestic work even earlier.

Doxiciclina para tratamento da doença inflamatória pélvica / Doxycycline for treatment of pelvic inflammatory disease

CONTEXTO: A Doença Inflamatória Pélvica (DIP) é uma síndrome clínica atribuída à ascensão dos microorganismos do trato genital inferior, com comprometimento do endométrio, trompas, anexos uterinos e/ou estruturas contíguas. Os microorganismos mais comumente envolvidos são Neisseria gonorrhoeae e Chlamydia trachomatis. A Organizaçao Mundial da Saúde (OMS) estima a ocorrência de 1.967.200 casos de clamídia e de 1.541.800 casos de gonorreia na população sexualmente ativa no Brasil, por ano. Dentre mulheres com infecções não tratadas por clamídia e/ou gonorreia, 10 a 40% desenvolvem doença inflamatória pélvica (DIP). A doxiciclina é um dos medicamentos recomendados pelo Ministério da Saúda para tratamento da DIP, mas ainda não é disponibilizado no SUS para essa indicação. TRATAMENTO RECOMENDADO: De acordo com o Manual de Controle das DST (2006)2, do Ministério da Saúde, os tratamentos recomendados para DIP leve, sem sinais de peritonismo ou febre (tratamento ambulatorial), deve ser realizado da seguinte forma: -Esquema 1: Ceftriaxona 250 mg, IM, dose única + Doxiciclina 100 mg, VO de 12/12 horas, por 14 dias + Metronidazol 500 mg, VO, de 12/12 horas, por 14 dias; -Esquema 2: Ofloxacina 400 mg, VO de 12/12 horas por 14 dias Ou Ciprofloxacina 500 mg 12/12horas por 14 dias + Doxiciclina 100 mg, VO de 12/12 horas por 14 dias + Metronidazol 500 mg, VO de 12/12 horas, por 14 dias. CONSIDERAÇÕES FINAIS: A doxiciclina é uma opção de tratamento para a doença inflamatória pélvica (DIP). As estimativas de impacto orçamentário anual resultante da ampliação de uso da doxiciclina no SUS, para tratamento da DIP provocada por clamídia e/ou gonorreia, variaram de R$274.528,36 até R$ 1.098.113,45. DELIBERAÇÃO FINAL: Os membros da CONITEC presentes na reunião do plenário do dia 11/06/2015 deliberaram, por unanimidade, recomendar a ampliação de uso da doxiciclina 100mg, em comprimido, para tratamento da doença inflamatória pélvica (DIP). DECISÃO: PORTARIA Nº 56, de 1 de outubro de 2015 - Torna pública a decisão de incorporar a doxiciclina 100mg comprimidos para tratamento da doença inflamatória pélvica (DIP), conforme normas técnicas definidas pelo Ministério da Saúde, no âmbito do Sistema Único de Saúde - SUS.

Enfermedad inflamatoria pélvica: un reto en el diagnóstico y tratamiento precoz / Pelvic inflammatory disease: a challenge in the early diagnosis and treatment

Actualizar los datos disponibles en referencia a la enfermedad inflamatoria pélvica para poder unificar criterios diagnósticos y terapéuticos y así minimizar las complicaciones que a corto y/o largo plazo puedan derivar. Método: Revisión de la literatura en Pubmed atendiendo sobre todo a las guías clínicas más actualizadas y ensayos clínicos aleatorizados. Resultados: La enfermedad inflamatoria pélvica es un cuadro infeccioso común entre las mujeres en edad fértil. Su mecanismo de transmisión más frecuente es la vía sexual y comparte factores de riesgo con otras enfermedades de transmisión sexual. Su diagnóstico, que es clínico, puede ser complejo y las formas subclínicas pueden pasar en ocasiones inadvertidas. Generalmente se puede comenzar con un tratamiento médico ambulatorio siguiendo las pautas recomendadas, y si la paciente no mejora o presenta un cuadro grave de inicio se indicará ingreso hospitalario y tratamiento médico endovenoso, reservando la cirugía para aquellos casos rebeldes en que fracasen los pasos anteriores. Conclusión: Es imprescindible reconocer esta entidad e instaurar el tratamiento antibiótico precoz, un retraso en el tratamiento adecuado, puede incrementar las secuelas inflamatorias a corto y largo plazo.

Update the pelvic inflammatory disease to standardize diagnostic and therapeutic criteria and to minimize its complications in the short and/or long term. Method: Search in Pubmed with especial attention to clinical guidelines and randomized clinical trials. Results: Pelvic inflammatory disease is a common infectious condition among women of fertile age. Its mechanism is the most common sexually transmitted shared risk factors and other sexually transmitted disease. Its clinical diagnosis can be complex and subclinical forms can sometimes go unnoticed. Usually it's indicated to start with medical treatment following the recommended guidelines, and if the patient does not improve or has a severe case, hospitalization and intravenous medical treatment is indicated, reserving surgery for those cases in which fail the above steps. Conclusion: It is essential to recognize this entity and establish early antibiotic treatment, so that a delay in appropriate antibiotic treatment, can lead to an increase in inflammatory short and long term sequelae.

Abordagem atual da doença inflamatória pélvica / Current approaches to pelvic inflammatory disease

A doença inflamatória pélvica (DIP) é um processo inflamatório de natureza infecciosa que pode atingir estruturas e órgãos do trato genital superior. Devido à sua importância epidemiológica e de suas graves complicações, este artigo atualiza e propõe uma abordagem sistemática da DIP. Os principais agentes etiológicos são a Neisseria gonorrhoeae,Chlamydia trachomatis e outros agentes etiológicos de uretrites, cervicites, vulvovaginites e vaginoses, em geral, polimicrobiana, o que é a base de sua terapêutica. A mulher deve ser investigada para DIP quando apresenta, especialmente, desconforto abdominal, dor lombar, dispareunia e nódoas ou manchas ao exame ginecológico, previamente a procedimentos transcervicais. A classificação clínico-laparoscópica deDIP pode ser dividida em: a) estágio I (endometrite/salpingite sem peritonite); estágio II (salpingite aguda com peritonite); estágio III (salpingite aguda com oclusão tubária ou abscesso tubo-ovariano); estágio IV (abscesso tubo-ovariano roto). A definição do estágio orienta a conduta e o tratamento, pois em formas leves (estágio I) o tratamento e seguimento podem ser feitos ambulatorialmente, enquanto para os casos moderadosou graves a internação hospitalar está indicada para início do tratamento por via endovenosa e monitorização da resposta ao tratamento. O tratamento suportivo, retirada de dispositivo intrauterino (DIU), abstinência sexual e repouso também são indicados, além de orientações sobre as implicações da doença e abordagem do parceiro.

Pelvic inflammatory disease (PID) is an inflammatory process of infectious nature that can affect structures and organs of the upper genital tract. Considering this disease's epidemiological relevance and severe complications, this article provides an update and proposes a systematic approach to PID. The main etiological agents are Neisseria gonorrhoeae, Chlamydia trachomatis and other etiological agents of urethritis, cervicitis, vulvovaginitis and vaginoses. These are generally of polymicrobial origin, which determines the treatment basis for pelvic inflammatory diseases.Women must be checked for PID when experiencing abdominal discomfort, backache, dyspareunia, or presenting with stains during gynecological examination and prior to transcervical procedures. The clinical and laparoscopic classification of PID can be divided into: a) stage I (endometritis/salpingitis without peritonitis), stage II (acute salpingitis with peritonitis), stage III (acute salpingitis with tubal occlusion or tube-ovarian abscess), and stage IV (tube-ovarian abscess rupture). Defining the stage guides procedures and treatment, given that in mild forms (stage I) the treatment and follow-up can be performed in the ambulatory environment while moderate to severe cases require hospitalization so that intravenous treatment and treatment outcome monitoring can be started. Supportive treatment, removal of intrauterine device (IUD), sexual abstinence and rest are also indicated, as well as counseling on the implications of the disease and partner approach.

Daily dose of clindamycin versus standard divided doses in obstetrical and gynecological infections: a retrospective cohort study.

To compare the rates of cure of septic abortion and pelvic inflammatory disease using a daily dose of clindamycin with gentamicin versus divided doses, we conducted a retrospective cohort study, where the electronic records of 661 patients who used clindamycin 1 × , 3 × or 4 ×/day (groups 1, 3 and 4, respectively) between September 2002 and August 2010 were analysed. Major outcomes included rates of cure and failure according to the clinical records. Secondary endpoints were percentage of adverse effects related to medication regimen and the prevalence of positive VDRL and HIV. Similar conditions were observed in all groups - septic abortion: 167/116/123; pelvic inflammatory disease: 73/95/87 (groups 1, 3 and 4, respectively). No significant difference was found among groups for age or for rate of cure. Rates of cure (cure/total [rate (95%CI)]) in groups 1, 3 and 4 were 236/240 [0.983 (0.957-0.993)], 205/211 [0.971 (0.939-0.986)], 203/210 [0.966 (0.932-0.983)], respectively. Days of use of clindamycin was significantly reduced in group 1, compared to groups 3 and 4 (2.6 ± 1.3 vs. 3.5 ± 2.5 vs. 3.3 ± 1.9-mean ± SD; p < 0.0001 - ANOVA), but this may be due to differences in how length of therapy was measured and not the effect on clinical cure.

Estudio Clínico-Ultrasónico transvaginal - anatomopatológico en las afecciones ginecológicas / Transvaginal- Ultrasonic- Anatomopatological Clinical Study in the gynecological conditions

Introducción: el ultrasonido transvaginal es un magnífico método para la evaluación de la mayoría de las estructuras presentes en la pelvis femenina. Objetivo: confirmar la presencia de alteraciones ginecológicas, que se sospechaban por la clínica y el examen físico. Métodos: se realizó un estudio descriptivo a 136 pacientes que asistieron a la consulta del Hospital Ginecobstétrico Fe del Valle, Manzanillo, entre enero y diciembre de 2011 con uso del ultrasonido transvaginal. Se estudiaron la edad, paridad, inicio de relaciones sexuales precoces, resultados del examen físico, hallazgos ecográficos y anatomopatológicos. Resultados: las enfermedades ginecológicas ocurrieron más en el grupo de 30 a 39 años (n=71; 52.20 por ciento); las afecciones ginecológicas predominaron en las que tenían 3 o más embarazos (n=53; 38.9 por ciento). La EIP fue más frecuente en las que iniciaron relaciones sexuales antes de los 18 años (n=20; 68.9 por ciento). Predominó del tumor tactable más los trastornos menstruales con 50 pacientes (36.7 por ciento), en las pacientes con miomas uterinos, el hallazgo ecográfico más frecuente fue el útero aumentado de tamaño (n=70; 85.36 por ciento). De las 136 mujeres estudiadas, en 120 coincidió el diagnóstico clínico con los resultados ecográficos. Conclusiones: las alteraciones ginecológicas fueron frecuentes entre los 30 y 39 años, en las multíparas, presentándose como signos y síntomas el tumor tactable más trastornos menstruales y el dolor más leucorrea. En el útero, la imagen nodular ecogénica localizada fue más frecuente; en ovarios, la imagen ecolúcida y las trompas engrosadas ecogénicas. Las afecciones más frecuentes encontradas por ecografía fueron el mioma uterino, la enfermedad inflamatoria pélvica y los quistes de ovarios; respectivamente(AU)

Introduction: because of the high sensitivity, high specificity, availability and low cost, of the transvaginal ultrasound, it appears the election technique in the initial study of the majority of the clinical manifestations of the woman, especially in her fertile age. Objective: to confirm the presence of gynecological alterations, that were suspected by the clinic and the physical examination. Methods: it was made a descriptive study whose universe was constituted by 136 patients that assisted to the preoperative consult in the gynecobstetric hospital Fe del Valle of Manzanillo, in the period between January and December of the 2011. It was applied a transvaginal ultrasound in addition to the anatomopatological examination in order to relate them. There were included the age, parity and the precocious sexual relations (before the 18 years), the symptomatology referred by the patient, the results of the physical examination, the echographic and anatomopathological findings. Results: the gynecological alterations were more frequent between the 30 and 39 years (n=71; 52,20 percent), being the multiparous the most affected (53 patients; 38,9 percent), presenting like signs and fundamental symptoms the tumor, more menstrual disorders and the pain with leucorrhea (n=50; 36,7 percent). In the uterus the echogenic nodular image located was presented with greater frequency (n=70; 85,36 percent). The most frequent conditions found by the echography were, the uterine myoma(n=82; 60,29 percent) and the pelvic inflamatory disease (68,9). Conclusions: the gynecological alterations were more frequent between the 30-39 years, in the multiparous. The most frequent symptoms were the menstrual disorders and the pain with leucorrhea. The more frequent echographic images in the uterus was the echogenic nodular image located. The most frequent alterations were the uterine myoma and the pelvic inflamatory disease. There was coincidence between the initial clinical (EU)

Actinomicosis pelviana: caso clínico / Pelvic actinomycosis: a case report

La actinomicosis pelviana es una enfermedad granulomatosa crónica muy infrecuente, causada por un bacilo Gram positivo, y que clínicamente suele confundirse con neoplasias pelvianas. Se presenta un caso clínico en que sospechó la infección en forma temprana, logrando resultados exitosos con tratamiento médico.

Pelvic actinomycosis is a chronic granulomatous disease quite uncommon; it is caused by positive Gram bacilli, and clinically it may appear as a pelvic neoplasia. We present a case report in which the infection was pursued actively, achieving excellent results with medical treatment.

Doença inflamatória pélvica: atualização / Inflammatory pelvic disease: updating

A doença inflamatória pélvica (DIP) consiste em espectro de infecções do trato genital superior que inclui: endometrite, salpingite, abscesso tubo-ovariano e/ou peritonite pélvica. Constitui-se em infecção polimicrobiana do trato genital superior feminino devido à sua contaminação pelos microrganismos do endocérvice e da vagina. São fatores de risco para o desenvolvimento de DIP: idade entre 15-24 anos, vida sexual ativa, múltiplos parceiros, inserção de dispositivo intra-uterino (DIU) há menos de 20 dias e história pregressa de DIP. Procedimentos e cirurgias pélvicos com manipulação de canal cervical podem predispor à infecção por alterarem a barreira cervical protetora. A DIP é um dos processos infecciosos mais frequentes nas mulheres em idade reprodutiva e é entidade de difícil diagnóstico devido às manifestações clínicas diversas. O diagnóstico é muito provável diante de dor à palpação cervical, uterina e/ou de anexos, acompanhados de febre, corrimento vaginal mucopurulento ou leucorreia, sangramento intermenstrual e pós-coito, dispareunia, disúria e polaciúria. O tratamento da DIP deve prover antibioticoterapia empírica de amplo espectro para os patógenos mais prováveis: N. gonorrhoeae e C. trachomatis, pois o rastreamento negativo para esses organismos não exclui infecção do trato reprodutivo superior. A precocidade das medidas terapêuticas é importante na prevenção de sequelas de longo prazo e a opção por tratamento ambulatorial ou hospitalar deve ser baseada no julgamento médico. Parceiros sexuais de mulheres com DIP devem ser examinados e tratados caso tenham tido relação sexual com a paciente nos 60 dias anteriores ao aparecimento dos sintomas. O rastreamento e tratamento da infecção por clamídia em mulheres sexualmente ativas diminui o risco de elas contraírem DIP. Grávidas com suspeita de DIP devem ser internadas para receber tratamento parenteral. Não foram estabelecidas diferenças nas manifestações clínicas da DIP em mulheres soropositivas e negativas para o HIV. Ambos os grupos respondem igualmente bem aos tratamentos parenteral e oral. (AU)

Pelvic Inflammatory Disease (PID) consists in a spectrum of upper genital tract infections including: endometritis, salpingitis, tube-ovarian abscess and / or pelvic peritonitis. It constitutes polymicrobial infection of upper female genital tract because of its contamination by microrganisms from the vagina and endocervix. Risk factors for the development of PID are: aged 15-24 years, sexual activity, multiple partners, insertion of an intrauterine device (IUD) for less than 20 days and a history of PID. Procedures and pelvic surgery with manipulation of the cervical canal may predispose to infection by altering the cervical protective barrier. PID is one of the most common infectious processes in women in reproductive age and it is an entity of difficult diagnosis due to the diverse clinical manifestations. The diagnosis is most likely on painful palpation of the cervix, uterus or attachments, accompanied by fever, depurulent vaginal discharge or leukorrhea, intermenstrual and postcoital bleeding, dyspareunia, dysuria and pollakiuria. The treatment of PID should provide broad-spectrum empiric antibiotic therapy for the most likely pathogens: N. gonorrhoeae and C. trachomatis, because negative screening for these organisms does not exclude infection of the upper reproductive tract. The early therapeutic measures are important in preventing long-term sequelae and the option for outpatient or hospital treatment should be based on medical judgment. Sexual partners of women with PID should be examined and treated if they had sexual relations with the patient 60 days prior to the onset of symptoms. Screening and treatment of chlamydial infection in sexually active women decreases the risk of them contracting PID. Pregnant women with suspected PID should be hospitalized to receive parenteral treatment. No differences were found in clinical manifestations of PID in women seropositive and negative for HIV. Both groups respond equally well to parenteral and oral treatments. (AU)

Doença inflamatória pélvica / Pelvic inflammatory disease

Doença inflamatória pélvica é causada pela infecção polimicrobiana do trato genital superior.Os agentes patogênicos são sexualmente transmissíveis (clamídia, gonococo e micoplasmas) e endógenos (aeróbios, anaeróbios e facultativos).O envolvimento de germes sexualmente transmissíveis preceitua o rastreamento das demais doenças sexualmente transmissíveis em todas as pacientes e seus parceiros.A prevalência da forma subclínica aumenta o risco de falta de diagnóstico e subestimação.Vaginose bacteriana e instrumentação uterina aumentam o risco.Canal cervical com corrimento branco, amarelado ou sangramento induzido indicam infecção por clamídia, gonococo ou micoplasmas.O tratamento deve ser instituído quando estão presentes dores à palpação do baixo ventre ou anexial e à mobilização do colo uterino.O tratamento precoce se justifica porque a infecção experimental mostra que as lesões tubárias não revertem com antibióticos administrados 12 dias depois da inoculação de clamídia.

[Fallopian tube primary invasive adenocarcinoma associated with acute inflammatory pelvic disease. Case report and literature review]. / Adenocarcinoma invasor primario de trompa de falopio concomitante con enfermedad pélvica inflamatoria aguda. Comunicación de un caso y revisión de la bibliografía.

The primary fallopian tube invader adenocarcinoma is a preoperative diagnosis rarely reported in the literature, because is the most uncommon of all gynecological tumors, with prevalence from 0.3 to 1.8%. Since its clinical evolution is very unspecific, in general this tumor is diagnosed during a laparothomy for other purpose or by the pathologist in the final histopathological report. The most frequent signs and symptoms are abdominal pain or a pelvic mass in 80% of cases; transvaginal bleeding in 50%, intense transvaginal serohematic discharge (hidrops tubae profluens) in 11.1%, and peritonitis in pelvis in 3.7%. In 25 to 60% of the cases a report of adenocarcinoma in the pap smear with negative endometrial biopsy can be found. The treatment is predominantly surgical, as that of epithelial ovarian carcinoma, and consists of an intraperitoneal washing, total abdominal hysterectomy with bilateral salpingo-oophorectomy and a proper staging. It is required an omentectomy with pelvic and paraaortic lymphadenectomy in systematic way. In the more advanced stages III and IV that required a radical debulking, we have to be very emphatic in citoreduction. In some cases, as the persistence or recurrence of illness, it can be necessary adjuvant chemotherapy. In some patients in early stage I or II with low risk, the complete staging could not be necessary. There is controversy about administration criteria of adjuvant treatment, since there is not evidence of survival increase related to its use. The five years survival rate was 64% for stage I, 42% for stage II, 32% for stage III, and 17% for stage IV. Fallopian tube malignancies are rare and involve a poor prognosis.

Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial.

OBJECTIVE: To evaluate the equivalence of ceftriaxone plus doxycycline or azithromycin for cases of mild pelvic inflammatory disease (PID). METHODS: Patients with PID received an intramuscular injection of 250 mg of ceftriaxone, and were randomly assigned to receive 200 mg/d of doxycycline for 2 weeks, or 1 g of azithromycin per week, for 2 weeks. The degree of pain was assessed on days 2, 7, and 14 and clinical cure was assessed on day 14. RESULTS: From 133 patients eligible for the study, 13 were excluded for having conditions other than PID, 11 were lost on follow-up, and three had oral intolerance to the antibiotics, yielding 106 for protocol analysis. No significant difference was observed regarding the degree of pain between the doxycycline and azithromycin groups. Clinical cure per protocol was 98.2% (56 of 57; 95% confidence interval [CI], 0.9-0.99) with azithromycin, and 85.7% (42 of 49; 95% CI, 0.72-0.93) with doxycycline (P=0.02). In a modified intention to treat analysis, clinical cure was 90.3% (56 of 62; 95% CI, 0.80-0.96) with azithromycin, and 72.4% (42 of 58; 95% CI, 0.58-0.82) with doxycycline (P=.01); a relative risk of 0.35, and a number needed to treat of six for benefit with azithromycin. CONCLUSION: When combined with ceftriaxone, 1g of azithromycin weekly for 2 weeks is equivalent to ceftriaxone plus a 14-day course of doxycycline for treating mild PID.

Síndrome de congestión pélvica: Evaluación del dolor después del tratamiento laparoscópico con Ligasure® / Pelvic inflammatory disease: evaluation of pain after laparoscopy therapy with Ligasure(R)

Objetivo: Evaluar el dolor pélvico después de utilizar la técnica con Ligasure® de la ligadura de las venas ováricas varicosas por laparoscopia en mujeres con síndrome de congestión pélvica en una clínica de Cali, entre junio de 2002 y junio de 2003. Tipo de estudio: Ensayo clínico no controlado. Materiales y métodos: Se realizó laparoscopia operatoria a 29 pacientes con clínica de síndrome de congestión pélvica y evaluación de la intensidad del dolor con la escala visual análoga cromática, a través de una encuesta antes y 6 meses después del procedimiento. A 28 se les realizó varicocelectomía con técnica de Ligasure® por evidencia de varicocele pélvico y a una paciente se evidenció endometriosis. El promedio de edad de las pacientes fue 33.8 años. La información se procesó en Epi-Info 6.4. El análisis de la diferencia entre los valores de la intensidad del dolor antes y después del procedimiento quirúrgico fue realizado con la prueba chi cuadrado (c) con un nivel de significancia de 95/100 y el valor de p <0.05 considerado estadísticamente significante.Resultados: Después del procedimiento, los valores de la intensidad del dolor en la escala disminuyeron, siendo la mayoría <6 (26 pacientes). Al final del período de observación, ninguna de las pacientes había establecido un valor en la escala de 0 (sin dolor). Haciendo la comparación antes y después del procedimiento, hubo diferencia significativa en la disminución de la intensidad del dolor después de la cirugía (con prueba c² de 43.13 con 4 grados de libertad y valor de p<0.05).Conclusión: El presente estudio muestra que el dolor se reduce significativamente después de la ligadura de las venas ováricas varicosas por laparoscopia con técnica de Ligasure®, considerándose un método optativo efectivo en el tratamiento del síndrome de congestión pélvica

STD trends and patterns of treatment for STD by physicians in private practice in Peru.

OBJECTIVES: To describe trends in STD visits to physicians in private practice in Peru over a 15 year period and in the patterns of treatments used for STD. METHODS: IMS Health conducts for pharmaceutical marketing purposes surveys of a random cluster sample of 1.63% of practising physicians in Peru, stratified by region and specialty. Physicians record details of diagnoses and treatments for all patients seen during a 7 day period every 6 months. Data collected on selected STD syndromes were retrospectively reviewed over a 15 year period. RESULTS: The number of first visits for pelvic inflammatory disease (PID) and trichomoniasis, and total visits for genital herpes increased from 1983-5 to 1996-7; while first visits for gonorrhoea and total visits for syphilis have changed little in recent years. Treatment for gonorrhoea usually involved the use of spectinomycin or an aminoglycoside only. Treatments offered for PID were remarkably inadequate and for trichomoniasis often involved products not known to be effective for trichomoniasis or other causes of vaginal discharge. CONCLUSIONS: This form of active surveillance provides information potentially useful to guide policies for prevention and management of STDs and HIV infections in developing countries.